Abstract | BACKGROUND: METHODS: A total of 416 outpatients (271 women and 145 men) aged 25 to 65 years with DSM-III-R-defined, early-onset, primary dysthymia without concurrent major depression were randomized to 12 weeks of treatment with sertraline, imipramine, or placebo. RESULTS: Both active treatments resulted in significantly reduced scores on the 17-item Hamilton Rating Scale for Depression (P = .04 and P = .01 for sertraline and imipramine vs placebo, respectively), the Montgomery-Asberg Depression Rating Scale (P = .01 and P = .003 vs placebo, respectively), Hopkins Symptom Checklist (P < .05), and the self-rated version of the Inventory of Depressive Symptoms (P < .05). With the use of a Clinical Global impressions improvement score of 1 or 2 (very much or much improved) to define response, response rates were 59% for sertraline, 64% for imipramine, and 44% for placebo (P = .02 for sertraline vs placebo and P < .001 for imipramine vs placebo). A significantly greater proportion of patients receiving imipramine than those receiving sertraline or placebo discontinued treatment because of adverse events (P = .001 and P < .001, respectively). CONCLUSIONS:
|
Authors | M E Thase, M Fava, U Halbreich, J H Kocsis, L Koran, J Davidson, J Rosenbaum, W Harrison |
Journal | Archives of general psychiatry
(Arch Gen Psychiatry)
Vol. 53
Issue 9
Pg. 777-84
(Sep 1996)
ISSN: 0003-990X [Print] United States |
PMID | 8792754
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Placebos
- Serotonin Uptake Inhibitors
- 1-Naphthylamine
- Imipramine
- Sertraline
|
Topics |
- 1-Naphthylamine
(analogs & derivatives, therapeutic use)
- Adult
- Aged
- Ambulatory Care
- Chronic Disease
- Depressive Disorder
(drug therapy, psychology)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Imipramine
(therapeutic use)
- Male
- Middle Aged
- Personality Inventory
- Placebos
- Psychiatric Status Rating Scales
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Sertraline
- Treatment Outcome
|